Browse

The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung cancer.

Elsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded approval.

The purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients.